Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.
The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).
Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) – Global Forecast to 2023
In terms of Therapy, the global autoinjectors market can be segmented into:
- Rheumatoid Arthritis
- Multiple Sclerosis
- Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)
By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018
On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies such as migraines, cardiovascular diseases, psoriasis, and anemia. In 2018, the rheumatoid arthritis segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.
Get a sample PDF copy of the Report @: www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724
Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug. Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases. They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.
The geographical regions mapped in the report are:
- North America
- Rest of the World
North America to dominate the market in 2018
In 2018, North America is expected to account for the largest share of the autoinjectors market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, rising prevalence of anaphylaxis in the US, and rising prevalence of autoimmune and chronic diseases in the US and Canada are contributing to the large share of North America.
Leading players of Autoinjectors Market including:
- Abbvie (US)
- Amgen (US)
- Teva (Israel)
- Biogen (US)
- Eli Lilly (US)
- Mylan (US)
- J&J (US)
- Novartis (Switzerland)
- Bayer (Germany)
- Merck (Germany)
- Biogen (US)
- Ypsomed (Switzerland)
- SHL Group (Taiwan)
- Becton, Dickinson and Company (US)
Critical questions the report answers:
- Which are the most significant revenue-generating regions for the market?
- What are the significant upcoming trends in the market?
- How will the market drivers, restraints, and future opportunities affect the market dynamics?
- Which end-user segment is expected to witness maximum growth opportunities during the forecast period?
Request Sample Pages: www.marketsandmarkets.com/requestsampleNew.asp?id=173991724